DVA Related Analyst Ratings
-
Deutsche Bank Upgrades DaVita (DVA) to Buy
-
SunTrust Robinson Humphrey Downgrades DaVita (DVA) to Neutral
-
Deutsche Bank Downgrades DaVita (DVA) to Hold
-
Goldman Sachs Downgrades DaVita (DVA) to Neutral
-
Bernstein Starts DaVita (DVA) at Market Perform
-
JPMorgan Starts DaVita (DVA) at Overweight
-
Nomura Securities Upgrades DaVita (DVA) to Buy
-
Wells Fargo Maintains an 'Outperform' on DaVita (DVA); Favorable Settlement in Texas Qui Tam Suit
-
Deutsche Bank Maintains 'Top Pick' on DaVita (DVA); Raising PT on Pending HealthCare Partners Acquisition
-
Auriga Maintains a 'Buy' on Affymax, Inc. (AFFY); Milestone Payments Drive Q1 Upside; Continue Seeing Market Opp for Omontys
-
DaVita (DVA) Shares Lower as Baird, Feltl Downgrades Weigh
-
Feltl & Co Downgrades DaVita (DVA) to Buy
-
UBS Maintains a 'Buy' on DaVita (DVA); Solid Results; Now Focus Shifts to Integrated Care
-
Nomura Securities Maintains a 'Neutral' on DaVita (DVA); Q4 Review
-
Nomura Securities Starts DaVita (DVA) at Neutral, Price Target Offers 6.4% Upside
-
Raymond James Reiterates an 'Outperform' on Amgen (AMGN); DaVita Contract Revelation Indicates Near-Term Upside on EPO Pricing
-
Baird Upgrades DaVita (DVA) to Outperform
-
Citi Downgrades DaVita (DVA) to Hold
-
Deutsche Bank reiterates a 'Buy' on DaVita (DVA); Trimming PT to Reflect Multiple Contraction
-
Raymond James Upgrades DaVita (DVA) to Outperform
-
Piper Jaffray Upgrades DaVita (DVA) to Overweight
-
Jefferies Upgrades DaVita (DVA) to Buy
-
William Blair Starts DaVita (DVA) at Outperform
-
Proposed Reimbursement changes for ESAs Another Setback for Amgen (AMGN) - Goldman Sachs
-
UBS Reiterates a 'Buy' on DaVita (DVA); Revising EPS Post QIP
-
Piper Jaffray Upgrades DaVita (DVA) to Neutral
-
Jefferies Maintains a 'Hold' on DaVita (DVA); Good Q1 Bundled with Capital Markets Day Should Provide Nice Boost to Shares
-
Jefferies Raises Price Target on DaVita (DVA), Believes Good News Is Already Priced In
-
Deutsche Bank Raises Price Target on DaVita (DVA), Raises FY11 EPS Estimate by 15%
-
Collins Stewart Starts MEDNEX (MD), DaVita (DVA), Lab Corp. (LH), Fresenius (FMS) at Buy, Quest (DGX) at Hold
-
Jefferies Raises Price Target on DaVita (DVA), Maintains Hold Rating
-
Avondale Partners Starts DaVita (DVA) at Market Perform
-
Goldman Sachs Starts DaVita (DVA) at Buy, Sees 26% Upside
-
Baird Starts DaVita (DVA) at Neutral, Price Target $79
-
Piper Jaffray Downgrades DaVita, Inc. (DVA) to Underweight
-
Feltl & Co Initiates Coverage on Medical Appliances & Equipment Stocks (DVA, FMS & NXTM)
-
Citi Reiterates a 'Buy' on DaVita Inc (DVA); Dialysis Final Rule Better than Proposed, but Not Perfect
-
Citi Maintains a 'Buy' Rating on DaVita Inc (DVA); Cliff Notes for ESRD Final Rule
-
Raymond James Downgrades DaVita (DVA) to Market Perform
-
Jefferies & Co Downgrades DaVita (DVA) to Hold
-
UBS Maintains a 'Buy' on DaVita (DVA); Makes Adjustments After Taking a More Detailed View of Bundling
-
Deutsche Bank Reiterates a 'Buy' on DaVita (DVA); Raises PT & Estimates
-
Leerink Swann Initiates Coverage on Davita (DVA) with a Market Perform; Keeping Near-term Bundling Expectation
-
Stifel Nicolaus Initiates Coverage on DaVita (DVA) with a Buy
-
Bank of America Initiates Coverage on Several Hospitals
-
Piper Jaffray Upgrades DaVita Inc. (DVA) to Buy; Expect Strong Q1 Results
-
Matrix Lighthouse Rating Changes 2/17
-
RBC Capital Initiates Coverage on DaVita (DVA) with an Outperform
-
Matrix Lighthouse Rating Changes 1/8
-
Matrix Lighthouse Rating Changes 11/12
Back to DVA Stock Lookup
